U Mey
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Moccia A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematol Oncol 2020; 39:196-204.
Dec 23, 2020Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Dec 23, 2020Hematol Oncol 2020; 39:196-204
Moccia A A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli Stefanie, Güsewell Sabine, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr Martin, Fischer N, Ghilardi G, Krasniqi F, Hitz Felicitas
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
Aug 27, 2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Aug 27, 2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst T, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92:1033-40.
Apr 17, 2013Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
Apr 17, 2013Ann Hematol 2013; 92:1033-40
Hitz F, Mey U, Zucca E, Berardi Vilei S, Eckhardt K, Berthod G, Caspar C, Pabst Th, Fischer N, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland